• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Clinical Trial Listings
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • JobWatch
    • White Papers
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Trial Listings
  • Advertise
  • COVID-19
  • iConnect
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » ZS Genetics expands with new Massachusetts facility

ZS Genetics expands with new Massachusetts facility

July 10, 2013
CenterWatch Staff

ZS Genetics, a developer of a Third-Generation DNA sequencing platform, has opened a new office and laboratory facility in Wakefield, Mass., a milestone in the company’s transition from R&D to product commercialization.

The Wakefield facility brings together employees who currently work remotely and also provides sufficient expansion space to accommodate the company’s anticipated growth. “This facility represents a new chapter in the life of this company,” said Bill Ward, president of ZS Genetics.

The new office will also bring in new opportunities for ZS Genetics. “Massachusetts is a hub for life sciences and technology expertise. Having access to the talent and resources available in the Boston area was a critical factor in our decision to locate here,” noted William Glover, chief executive officer of ZS Genetics. “We are moving into this facility with a dozen employees and will be looking to expand our workforce in the near future.”

Through the Massachusetts Life Sciences Center (MLSC), Massachusetts is investing $1 billion over 10 years in the growth of the state’s life sciences supercluster. These investments are being made under the Massachusetts Life Sciences Initiative, proposed by Governor Patrick in 2007, and passed by the State Legislature and signed into law by Governor Patrick in 2008.

“Congratulations to the ZS Genetics team on the grand opening of their first ‘bricks and mortar’ office,” said MLSC President & CEO Dr. Susan Windham-Bannister.

ZS Genetics’ 10,000-square-foot space includes office and cubicle space for employees, as well as facilities for a chemistry lab and a DNA sample preparation lab. The facility will house state-of-the-art equipment, including two electron microscopes, to develop the company’s platform.

The company’s team has grown substantially over the past several months to 10 employees as the company has added key personnel required for building the “alpha” version of its sequencing system, including Dr. Suhaib Siddiqi, a chemist who will lead one of the R&D teams, and Dr. Larry Scipioni, who will run the microscope labs.

ZS Genetics is a privately held Massachusetts startup that has developed the components and intellectual property for the Third Generation of DNA sequencing. This patented approach combines the power of electron beam microscopy with proprietary nucleic acid labeling processes to read DNA sequences directly from images. ZS Genetics’ long-read, single-molecule technology offers the prospect of significant advancements in genetic analysis, with implications in the DNA sequencing and diagnostics market.

 

Upcoming Events

  • 24May

    Powering an Effective Oversight Strategy with Clinical and Operational Insights

  • 25May

    2022 WCG Avoca Quality & Innovation Summit: Own the Future

  • 28Jun

    Effective Root Cause Analysis and CAPA Investigations for the Life Sciences

  • 16Oct

    WCG MAGI's Clinical Research Hybrid Conference - 2022 West

Featured Products

  • Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

    Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

  • Surviving an FDA GCP Inspection

    Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

Featured Stories

  • Protocol-360x240.png

    Avoid Deviations by Making Protocol Review a Team Effort

  • SelectionProcess-360x240.png

    Give Us a Voice: Sites Clamor for a Say on Vendor Selection

  • Convince-360x240.png

    Use Data and Details to Convince Site Leadership to Add Staff

  • AsktheExpertsBadge-360x240.png

    Ask the Experts: Listing Trial Staff and Others on the Statement of Investigator

Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

The information you need to adapt your monitoring plan to changing times.

Learn More Here
  • About Us
  • Contact Us
  • Privacy Policy
  • Do Not Sell My Personal Information

Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 617.948.5100 – Toll free 866.219.3440

Copyright © 2022. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing